Cetera Investment Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History

Cetera Investment Advisers’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$427K	Buy	19,198 +2,843	+17%	+$67.9K	﹤0.01%	3655
2025 Q4	$437K	Buy	16,355 +436	+3%	+$10.4K	﹤0.01%	3552
2025 Q3	$340K	Buy	15,919 +3,156	+25%	+$74.6K	﹤0.01%	3732
2025 Q2	$275K	Buy	12,763 +931	+8%	+$17.3K	﹤0.01%	3470
2025 Q1	$197K	Buy	+11,832	New	+$215K	﹤0.01%	3614
2024 Q2	–	Sell	-11,559	Closed	-$214K	–	3726
2024 Q1	$214K	Buy	+11,559	New	+$286K	﹤0.01%	3309

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Cetera Investment Advisers's ACAD Position: Q1 2026 in Review

Cetera Investment Advisers increased its Acadia Pharmaceuticals (ACAD) stake by 17% in Q1 2026, buying an estimated $67.9K and bringing the position to 19,198 shares worth $427K. The position accounts for ﹤0.01% of the portfolio, ranked #3655.

Cetera Investment Advisers first reported a position in ACAD in Q1 2024 and has held it in 6 quarters since. The position peaked at $437K in Q4 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Cetera Investment Advisers held 19,198 shares of Acadia Pharmaceuticals worth $427K as of Q1 2026.
Cetera Investment Advisers bought 2,843 Acadia Pharmaceuticals shares in Q1 2026, an estimated $67.9K.
Acadia Pharmaceuticals made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #3655 holding.
Cetera Investment Advisers first reported a position in Acadia Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
Cetera Investment Advisers's Acadia Pharmaceuticals position peaked at $437K in Q4 2025.
340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.